facebook button CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation

Sponsor: Amgen Inc.

Protocol 20190009. A phase 3 multicenter, randomized, open label, active-controlled, atudy of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with mutated KRAS p.G12C.